ALK and non-small cell lung carcinoma: Recently, an international survey was conducted among medical, clinical, and radiation oncologists, and neurosurgeons, regarding treatment recommendations for asymptomatic brain metastases in EGFR mutant or ALK-positive NSCLC patients, demonstrating a differential preferred approach according to different specialists in specific clinical scenarios [35].